Novel agents for managing dyslipidaemia

Bibliography

• TUNSTALL-PEDOE H, KUULASMAA K, MAHONEN M, TOLONEN H, RUOKOKOSKI E, AMOUYEL P: Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations. Lancet (1999) 353:1547–1557.
   PubMed Web of Science ®Google Scholar
• AMOS AF, MCCARTY DJ, ZIMMET P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet. Med. (1997) 14\(Suppl. 5): S1–S85.
   Google Scholar
• SUTANEGARA D, BUDHIARTA AA: The epidemiology and management of diabetes mellitus in Indonesia. Diabet. Res. Clin. Pratt (2000) 50\(Suppl. 2):S9–S16.
   Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL STUDY GROUP: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simyastatin Survival Study. Lancet (1994) 344:1383–1389.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA (1998) 279:1615–1622.
   Google Scholar
• SACKS FM, PFEFFER MA, MOYB LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol. N Engl. J. Med. (1996) 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of cholesterol levels. N Engl. J. Med. (1998) 339:1349–1357.
   PubMed Web of Science ®Google Scholar
• RUBINS HB, ROBINS SJ, COLLINS D et al.: Gemflbrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. (1999) 341:410–418.
   PubMed Web of Science ®Google Scholar
• PITT B, WATERS D, BROWN WV et al: Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atoryastatin versus Reyascularization Treatment Investigators. N Engl. J. Med. (1999) 341:70–76.
   PubMed Web of Science ®Google Scholar
• SCHWARZ GG, OLSSON AG, EZEKOWITZ MD etal.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomised controlled trial. JAMA (2001) 285:1711–1718.
   Google Scholar
• PEDERSEN TR, OLSSON AG, FAERGEMAN 0 et al: Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simyastatin Survival Study (4S). Circulation (1998) 97:1453–1460.
   PubMed Web of Science ®Google Scholar
• SACKS FM, MOYB LA, DAVIS BR et al: Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. Circulation (1998) 97:1446–1452.
   PubMed Web of Science ®Google Scholar
• BROWN WV: Cholesterol lowering in atherosclerosis. Am. J. Cordial (2000) 86:29H–32H.
   Google Scholar
• BEAIRD SL: HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J. Am. Pharm. Assoc. (Wash) (2001) 40:637–644.
   Google Scholar
• OLSSON AG: Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin rosuvastatin. Am. J. Cordial (2001) 87\(Supp1.1):33B–36B.
   Google Scholar
• KAJINAMI K, KOIZUMI J, UEDA K et al: Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am. J. Cardiol (2000) 85:178–183.
   PubMed Web of Science ®Google Scholar
• HIYOSHI H, YANAGIMACHI M, ITO M et al: Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-coa reductase inhibitors. J. Lipid Res. (2000) 41:1136–1144.
   PubMed Web of Science ®Google Scholar
• UGAWA T, KAKUTA H, MORITANI H et al.: YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br. J. Pharmacol (2000) 131:63–70.
   PubMed Web of Science ®Google Scholar
• SHARMA A, SLUGG PH, HAMMETT JL,JUSKO WJ: Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J. Clin. Pharmacol (1998) 38:1116–1121.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, DICKLIN MR, MAKI KC, KLEINPELL RM: Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin. Investig. Drugs (2000) 9:2663–2671.
   PubMed Web of Science ®Google Scholar
• FAYARD E, SCHOONJANS K, AUWERX J: Xol INXS: role of the liver X and the farnesol X receptors. Cun: Opin. (2001) 12:113–120.
   Web of Science ®Google Scholar
• •Reviews bile acid metabolism and its control.
   Google Scholar
• HIGAKI J, HARA S, TAKASUN et al: Inhibition of ileal Na±/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits. Arterioscler. Thromb. Vase. Biol. (1998) 18:1304–1311.
   PubMed Web of Science ®Google Scholar
• LIPKA LJ, LEBEAUT AP VELTRI EP etal.: Reduction of LDL-cholesterol and elevation of HDL-cholesterol in subjects with primary hypercholesterolemia by ezetimibe (SCH 58235): pooled analysis of two phase II studies. J. Am. Coll. Cordial (2000) 35(Suppl. A):257A.
   Google Scholar
• DAVIS HR, COMPTON DS, MOOS LM, TETZLOTT GG: Ezetimibe reduces plasma cholesterol and inhibits the development of atherosclerosis in ApoE knockout mice with and without LDL receptors. Circulation (2000) 102:11–186.
   PubMedGoogle Scholar
• KOSOGLOU T. MEYER I, MUSIOL B et al.: Coadministration of simvastatin and ezetimibe leads to significant reduction in LDL-cholesterol. Proceedings of the 3rd International Congress on Coronary Artery Disease: From Prevention to Intervention. Lyon, France (2000) p71.
   Google Scholar
• KESANIEMI YA, ENHOLM C, MIETTINEN TA: Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J. Clin. Invest. (1987) 80:578–581.
   PubMed Web of Science ®Google Scholar
• ORAM JF, LAWN RM: ABCAl. The gatekeeper for eliminating excess tissue cholesterol. J. Lipid Res. (2001) 42:1173–1179.
   PubMed Web of Science ®Google Scholar
• ••Review of ABC-Al and its role in lipidmetabolism.
   Google Scholar
• DROBNIK W, LINDENTHAL B, LIESER B et al: ATP-binding cassette transporter Al (ABCA1) affects total body sterol metabolism. Gastroenterology (2001) 120:1203–1211.
   PubMed Web of Science ®Google Scholar
• REPA JJ, TURLEY SD, LOBACCARO JMA et al.: Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 289:1524–1529.
   PubMed Web of Science ®Google Scholar
• •Importance of RXR in regulating cholesterol metabolism. 44.
   Google Scholar
• SCHULTZ JR, TU H, LUK A et a/.: Role of LXRs in control of lipogenesis. Genes Dev. (2000) 14:2831–2838.
   Google Scholar
• SCHARNAGL H, MARZ W, WIELAND H: Lifibrol: first member of a new class of lipid-lowering drugs? Expert Opin. Investig. Drugs (1997) 6:583–592
   Google Scholar
• LOCKER PK, JUNGBLUTH GL, FRANCOM SF, HUGHES GS JR: Lifibrol: a novel lipid-lowering drug for the therapy of hypercholesterolemia. Lifibrol Study Group. Pharmacal Ther. (1995) 57:73–88.
   Web of Science ®Google Scholar
• WINKLER K, SCHAEFER JR, KLIMA B et al.: HDL steady state levels are not affected, but HDL ApoAl turnover is enhanced by lifibrol in patients with hypercholesterolaemia and mixed hyperlipidaemia. Atherosclerosis (2000) 150:113–120.
   PubMed Web of Science ®Google Scholar
• VEGA GL, VON BERGMANN K, GRUNDY SM et al: Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol. J. Intern. Med. (1999) 246:1–9.
   PubMed Web of Science ®Google Scholar
• GORDON DJ, PROBSTFIELD JL, GARRISON RJ etal.: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation (1989) 79:8–15.
   Google Scholar
• PFEFFER MA, SACKS FM, MOYE LA et al.: Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol and Recurrent Events. Am. Coil. Cordial. (1999) 33:125–130.
   PubMed Web of Science ®Google Scholar
• ROBINS SJ, COLLINS D, WITTES JT etal.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomised controlled trial. JAMA (2001) 285:1585–1591.
   Google Scholar
• •HDL cholesterol on gemfibrozil treatment determines cardiovascular risk.
   Google Scholar
• BODEN WE: High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am. Cordial. (2000) 86:19L–22L.
   Google Scholar
• TALL AR: An overview of reverse cholesterol transport. Eur. Heart j (1998) 19(Suppl.A):A31–A35.
   Google Scholar
• •Reviews the co-ordinated regulation of cholesterol transport from periphery to liver.
   Google Scholar
• HIRANO K, YAMASHITA S, MATSUZAWA Y: Pros and cons of inhibiting cholesteryl ester transfer protein. Curr. Opin. Lipidal (2000) 11:589–596.
   PubMed Web of Science ®Google Scholar
• •Describes role of CETP in lipid metabolism.
   Google Scholar
• MAROTTI KR, CASTLE CK, BOYLE TP LIN AH, MURRAY RW, MELCHOIR GW: Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature (1993) 364:73–75.
   PubMed Web of Science ®Google Scholar
• OKAMOTO H, YONEMORI F, WAKITANI K, MINOWA T, MAEDA K, SHINKAI H: A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature (2000) 406:203–207.
   PubMed Web of Science ®Google Scholar
• MASSA MA, SPANGLER DP, DURLEY RC et al.: Novel heteroaryl replacements of aromatic 3-tetrafluoroethoxy substituents in trifluoro-3-(tertiaryamino)-2-propanols as potent inhibitors of cholesteryl ester transfer protein. Bioarg. Med. Chem. Lett. (2001) 11:1625-1628. KLIEWER SA, XU HE, LAMBERT MH, WILSON TM: Peroxisome proliferator-activated receptors: from genes to physiology. Recent. Frog. Harm. Res. (2001) 56:239-263. Review of PPAR system.
   Google Scholar
• OLIVER WR JR, SHENK JL, SNAITH MR et al.: A selective peroxisome proliferator-activated receptor 8 agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Li. USA (2001) 98:5306–5311.
   PubMed Web of Science ®Google Scholar
• MINNICH A, TIAN N, BYAN L, BILDER G: A potent PPAR alpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle. Am. I Physial Endocrthal Metab. (2001) 280:E270–E279.
   PubMed Web of Science ®Google Scholar
• ORAM JF: Novel approaches to treating cardiovascular disease: lessons from Tangier disease. Expert Opin. Investig. Drugs (2001) 10:427–438.
   PubMed Web of Science ®Google Scholar
• •Detailed review of the ABC-Al transporter.
   Google Scholar
• VENKATESWARAN A, LAFFITTE BA, JOSEPH SB etal.: Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc. Nail. Acad. Sci. USA (2000) 97:12097–12102.
   Google Scholar
• COSTET P, LUO Y, WANG N, TALL AR: Sterol-dependent transactivation of the ABCA1 promoter by the liver X receptor/ retinoid X receptor. j Biol. Chem. (2000) 275:28240–28245.
   PubMed Web of Science ®Google Scholar
• CHINETTI G, LESTAVEL S, BOCHER V etal.: PPAR-a and PPARy activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. (2001) 7:53–58.
   Google Scholar
• MUKHERJEE R, STRASSER J, JOWL, HOENER P, PATERNITI JR JR, HEYMAN RA: RXR agonists activate PPARa-inducible genes, lower triglycerides, and raise HDL levels in viva Arterioscler. Thromb. Vasc. Biol. (1998) 18:272–276.
   PubMed Web of Science ®Google Scholar
• CLAUDEL T, LEIBOWITZ MD, FIEVET C et al.: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Nat] Acad. Li. USA (2001) 98:2610–2615.
   PubMed Web of Science ®Google Scholar
• HURST RE: Bexarotene ligand pharmaceuticals. Cum: Opin. Investig. Drugs (2000) 1:514–523.
   PubMedGoogle Scholar
• HERMAN SI, GOPAL J, HAUGEN BR et al.: Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl. Med. (1999) 340:1075–1079.
   PubMed Web of Science ®Google Scholar
• ACTON S, RIGOTTI A, LANDSCHULZ KT, XU S, HOBBS HH, KRIEGER M: Identification of scavenger receptor SR-B1 as a high density lipoprotein receptor. Science (1996) 271:518–520.
   PubMed Web of Science ®Google Scholar
• CALVO D, GOMEZ-CORONADO D, LASUNCION MA, VEGA MA: CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (0xLDL and AcLDL) lipoproteins. Arteriascier. Thr0171b. V4SC. Biol. (1997) 17:2341–2349.
   Google Scholar
• SILVER DL, WANG N, XIAO X, TALL AR: High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B Type 1 results in selective sorting of HDL cholesterol from protein and polarised cholesterol secretion. j Biol. Chem. (2001) 276:25287–25293.
   PubMed Web of Science ®Google Scholar
• •Cell biochemistry of the final step in reverse cholesterol transport.
   Google Scholar
• MARD ONES P, QUINONES V, AMIGO L et al: Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B typel-deficient mice. I Lipid Res. (2001) 42:170–180.
   PubMed Web of Science ®Google Scholar
• KOZARSKY KF, DONAHEE MH, GLICK JM, KRIEGER M, RADER DJ: Gene transfer and hepatic overexpression of the HDL receptor SR-B1 reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arteciarder. Thr0171b. V4SC. (2000) 20:721–727.
   Google Scholar
• GODSLAND IF: Effects of postmenopausalhormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Feral Steril. (2001) 75:898–915.
   PubMed Web of Science ®Google Scholar
• •Extensive review of HRT effects on lipid metabolism.
   Google Scholar
• HULLEY S, GRADY D, BUSH T et al: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA (1998) 280:605–613.
   PubMed Web of Science ®Google Scholar
• DE LEO V, LA MARCA A, MORGANTE G, LANZETTA D, SETACCI C, PETRAGLIA F: Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am. J. Obstet. Cynecol. (2001) 184:350–353.
   PubMed Web of Science ®Google Scholar
• BJARNASON NH, HAARBO J, BYRJALSEN I, KAUFFMAN RF, KNADLER MP, CHRISTIANSEN C: Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits. Clin Endocrinol (Ox!) (2000) 52:225–233.
   PubMed Web of Science ®Google Scholar
• CLARKSON TB, ANTHONY MS, JEROME CP: Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J. Clin Endocnnol. Metab. (1998) 83:721–726.
   PubMed Web of Science ®Google Scholar
• CLIFTON-BLIGH PB, BABER RJ, FULCHER GR, NERY ML, MORETON T: The effect of isoflavones extracted from red clover (Rimostil) on lipid metabolism. Menopause (2001) 8:259–265.
   PubMed Web of Science ®Google Scholar
• BREWER HB JR: Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. Am. J. Cardiol (1999) 83:3F–12F.
   Google Scholar
• •Reviews pathophysiology of hypertriglyceridaemia.
   Google Scholar
• GENEST J JR, MCNAMARA JR, ORDOVAS JM et al: Lipoprotein cholesterol, apolipoprotein Al and B and lipoprotein (a) abnormalities in men with premature coronary heart disease. J. Am. Coll. Cardiol (1992) 19:792–802.
   PubMed Web of Science ®Google Scholar
• LAMARCHE B, TCHERNOF A, MAURIEGE P et al.: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA (1998) 279:1955–1961.
   PubMed Web of Science ®Google Scholar
• SACKS FM, ALAUPOVIC E MOYE LA et al.: VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 102:1886–1892.
   Google Scholar
• DAVIS RA, HUI TY: 2000 George Lyman Duff Memorial Lecture: Atherosclerosis is a liver disease of the heart. Arterioscler. Thromb. Vase Biol. (2001) 21:887–898.
   Google Scholar
• ••Describes assembly of ApoB containing lipoprotein particles.
   Google Scholar
• RAABE M, VENIANT MM, SULLIVAN MA et al.: Analysis of the role of microsomal triglyceride transfer protein in the tissue-specific knockout mouse. J. Clin Invest. (1999) 103:1287–1298.
   PubMed Web of Science ®Google Scholar
• TIETGE UJ, BAKILLAH A, MAUGEAIS C, TSUKAMOTO K, HUSSAIN M, RADER DJ: Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J. Lipid Res. (1999) 40:2134–2139.
   PubMed Web of Science ®Google Scholar
• BAKILLAH A, NAYAK N, SAXENA U, MEDFORD RM, HUSSAIN MM: Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist. Biochemistry (2000) 39:4892–4899.
   PubMed Web of Science ®Google Scholar
• ROBE JA, SULSKY R, SUN CQ et al: Anovel series of highly potent benzimidazole-based microsomal triglyceride transfer protein inhibitors. J. Med. Chem. (2001) 44:851–856.
   PubMed Web of Science ®Google Scholar
• JEPPESEN J, HEIN HO, SUADICANI E GYNTELBERG F: Triglyceride concentration and ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation (1998) 97:1029–1036.
   Google Scholar
• AUSTIN MA: Epidemiology of hypertriglyceridemia and cardiovascular disease. Am. J. Cardiol (1999) 83:13F–16F.
   Google Scholar
• •Includes meta-analysis of triglycerides as a risk factor for CHD.
   Google Scholar
• CULLEN P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am. J. Cardiol (2000) 86:943–949.
   PubMed Web of Science ®Google Scholar
• MANNINEN V, TENKANEN L, KOSKINEN P et al: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation (1992) 85:37–45.
   PubMed Web of Science ®Google Scholar
• THE BIP STUDY GROUP: Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation (2000) 102:21–27.
   PubMed Web of Science ®Google Scholar
• MILLER M: Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am. J. Cardiol (2000) 86:23L–27L.
   Google Scholar
• RUDEL LL, LEE RG, COCKMAN TL: Acyl coenzyme A: cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Cun: Opin. Lipidol (2001) 12: 121–127.
   Google Scholar
• •Review of ACAT and its role in lipid metabolism.
   Google Scholar
• AZUMA Y, DATE K, OHNO K, MATSUSHIRO S, YAMADA T: NTE-122, an acyl-coa: cholesterol acyltransferase inhibitor, prevents the progression of atherogenesis in cholesterol-fed rabbits. bit. Pharmacol (2001) 86:120–123.
   Google Scholar
• BOCAN TM, KRAUSE BR, ROSEBURY WS et al.: The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. Atherosclerosis (2001) 157:97–105.
   PubMed Web of Science ®Google Scholar
• FAZIO S, MAJOR AS, SWIFT LL etal.: Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. J. Clin. Invest. (2001) 107:163–171.
   Google Scholar
• INSULL W, KOREN M, DAVIGNON J et al.: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 157:137–144.
   PubMed Web of Science ®Google Scholar
• HAINER JW, TERRY JG, CONNELL JM et al: Effect of the acyl-CoA: cholesterol acyltransferase inhibitor DuP 128 on cholesterol absorption and serum cholesterol in humans. Clin. Pharmacol Ther. (1994) 56: 65–74.
   PubMed Web of Science ®Google Scholar
• KEMP BE, MITCHELHILL KI, MICHELL BJ, CHEN ZP, WITTERS LA: Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem. Sci. (1999) 24: 22–25.
   PubMed Web of Science ®Google Scholar
• •AMP kinase acts as a master switch for energy production from metabolic processes.
   Google Scholar
• BERGERON R, PREVIS SF, CLINE GW et al.: Effect of 5-aminoimidazole-4-carboxamide-l-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes (2001) 50:1076–1082.
   PubMed Web of Science ®Google Scholar
• STEINBERG D: LDL oxidation and its pathophysiologic significance. j Biol. Chem. (1997) 272:20963–20966.
   PubMed Web of Science ®Google Scholar
• WITZTUM JL, BERLINER JA: Oxidized phospholipids and isoprostanes in atherosclerosis. Cun: Opin. Lipidol (1998) 9:441–448.
   PubMed Web of Science ®Google Scholar
• BROWN AJ, JESSUP W: Oxysterols and atherosclerosis. Atherosclerosis (1999) 142:1–29.
   PubMed Web of Science ®Google Scholar
• GISSI-PREVENZIONE INVESTIGATORS: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet (1999) 354:447–455.
   PubMed Web of Science ®Google Scholar
• THE HEART OUTCOMES PREVENTION EVALUATION STUDY INVESTIGATORS: Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl. j. Med. (2000) 342:154–160.
   PubMed Web of Science ®Google Scholar
• BROWN BG, ZHAO XQ, CHAIT A et al.:Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study design. Can. J Cardiol. (1998) 14(Suppl.a6A–13A.
   Google Scholar
• MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur. Heart J. (1999) 20:725–741.
   Google Scholar
• PACKER L, WEBER SU, RIMBACH G: Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling. j. Nutr. (2001) 131:369S–373S.
   Google Scholar
• IULIANO L, PEDERSEN JZ, CAMASTRA C, BELLO V, CECCARELLI S, VIOLI F: Protection of low density lipoprotein oxidation by the antioxidant agent IRFI005, a new synthetic hydrophilic vitamin E analogue. Free Radic. Biol. Med. (1999) 26:858–868.
   PubMed Web of Science ®Google Scholar
• LEE CH, JEONG TS, CHOI YK etal.: Anti-atherogenic effect of citrus flavonoids, naringen and naringenin, associated with hepatic acat and aortic vcam-1 and mcp-1 in high cholesterol-fed rabbits. Biochem. Biophys. Res. Commun. (2001) 284:681–683.
   Google Scholar
• NOGUCHI N, NIKI E: Phenolic antioxidants: a rationale for design and evaluation of novel antioxidant drug for atherosclerosis. Free Radic. Biol. Med. (2000) 28:1538–1546.
   PubMed Web of Science ®Google Scholar
• CORNICELLI JA, TRIVEDI BK: 15-Lipoxygenase and its inhibition: a novel target for vascular disease. Cum: Pharm. Des. (1999) 5:11–20.
   Google Scholar